Immunogenicity and safety of a severe acute respiratory syndrome coronavirus 2 inactivated vaccine in healthy adults: randomized, double-blind, and placebo-controlled phase 1 and phase 2 clinical trials

Background: The significant morbidity and mortality resulted from the infection of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) call for urgent development of effective and safe vaccines. We report the immunogenicity and safety of an inactivated SARS-CoV-2 vaccine, KCONVAC, in healthy adults. Methods: Phase 1 and phase 2 randomized, double-blind, and placebo-controlled trials of KCONVAC were conducted in health) Chinese adults aged 18 to 59 years. The participants in the phase 1 trial were randomized to receive two doses, one each on Days 0 and 14, of either KCONVAC (5 or 10 mu g/dose) or placebo. The participants in the phase 2 trial were randomized to receive either KCONVAC (at 5 or 10 lag/dose) or placebo on Days 0 and 14 (0/14 regimen) or Days 0 and 28 (0/28 regimen). In the phase 1 trial, the primary safety endpoint was the proportion of participants experiencing adverse reactions/events within 28 days following the administration of each dose. In the phase 2 trial, the primary immunogenicity endpoints were neutralization antibody seroconversion and titer and anti-receptor-binding domain immunoglobulin G seroconversion at 28 days after the second dose. Results: In the phase 1 trial, 60 participants were enrolled and received at least one dose of 5-mu g vaccine (n = 24), 10-mu g vaccine (n = 24), or placebo (n = 12). In the phase 2 trial, .500 participants were enrolled and received at least one dose of 5-mu g vaccine (n = 100 for 0/14 or 0/28 regimens), 10-mu g vaccine (n = 100 for each regimen), or placebo (n = 50 for each regimen). In the phase 1 trial, 13 (54%), 11 (46%), and seven (7/12) participants reported at least one adverse event (AE) after receiving 5-,10-mu g vaccine, or placebo, respectively. In the phase 2 trial, 16 (16%),19 (19%), and nine (18%) 0/14-regimen participants reported at least one AE after receiving 5-,10-mu g vaccine, or placebo, respectively. Similar AE incidences were observed in the three 0/28-regimen treatment groups. No AEs with an intensity of grade 3+ were reported, expect for one vaccine-unrelated serious AE (foot fracture) reported in the phase 1 trial. KCONVAC induced significant antibod responses; 0/28 regimen showed a higher immune responses than that did 0/14 regimen after receiving two vaccine doses. Conclusions: Both doses of KCONVAC are well tolerated and able to induce robust immune responses in healthy adults. These results support testing 5-mu g vaccine in the 0/28 regimen in an upcoming phase 3 efficacy trial.